Entrada's Stock Craters as DMD Data Underperform Expectations, Handing Advantage to Novartis on May 07, 2026 Dystrophin ENTR-601 Entrada Therapeutics ' Muscular Dystrophy, Duchenne Novartis stock crash +
Entrada tightens focus on Duchenne, axes 20% of staff on May 01, 2025 Duchenne ENTR-601 exon Muscular Dystrophy Study on Hold United States Food and Drug Administration +
FDA Lifts Clinical Hold on Entrada's Duchenne Muscular Dystrophy Drug ENTR-601-44 After Two Years on February 24, 2025 Duchenne ELEVATE-44 ENTR-601 Entrada exon Muscular Dystrophy Phase 1b trial skipping Study on Hold United States Food and Drug Administration +